JP6681144B2 - 磁性抗体 - Google Patents
磁性抗体 Download PDFInfo
- Publication number
- JP6681144B2 JP6681144B2 JP2015050042A JP2015050042A JP6681144B2 JP 6681144 B2 JP6681144 B2 JP 6681144B2 JP 2015050042 A JP2015050042 A JP 2015050042A JP 2015050042 A JP2015050042 A JP 2015050042A JP 6681144 B2 JP6681144 B2 JP 6681144B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- magnetic
- compound
- metal
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000005291 magnetic effect Effects 0.000 title claims description 79
- 150000001875 compounds Chemical class 0.000 claims description 42
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 102000009109 Fc receptors Human genes 0.000 claims description 4
- 108010087819 Fc receptors Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 229910052751 metal Inorganic materials 0.000 description 19
- 239000002184 metal Substances 0.000 description 19
- VEUMANXWQDHAJV-UHFFFAOYSA-N 2-[2-[(2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol Chemical compound OC1=CC=CC=C1C=NCCN=CC1=CC=CC=C1O VEUMANXWQDHAJV-UHFFFAOYSA-N 0.000 description 17
- 229940125773 compound 10 Drugs 0.000 description 14
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- -1 metal complex compound Chemical class 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 150000004696 coordination complex Chemical class 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 9
- 229940125644 antibody drug Drugs 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000005307 ferromagnetism Effects 0.000 description 7
- 230000005389 magnetism Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000009175 antibody therapy Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000009987 spinning Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960002317 succinimide Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000005956 Cosmos caudatus Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910001507 metal halide Inorganic materials 0.000 description 2
- 150000005309 metal halides Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194005 Streptococcus sp. 'group G' Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000002946 anti-pancreatic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012529 protein A ELISA Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Description
なお、化3、化4の構造において、
移動相: 酢酸アンモニウム溶液0.1%:アセトニトリル(30:70)
カラム: C18 (30 mm× 2.1mm, 3.5 μm);流速 0.4 mL/min
質量分析の測定条件:
印加電圧 70 V
質量範囲 70.00 ― 2000.00
乾燥気流量 7 L/min
噴霧室圧力 25 psig
乾燥気体温度 300 ℃
毛細管電圧 3500 V
プロテインA:Protein A ELISA キット(コスモ・バイオ株式会社製)
プロテインAによる生成に用いた試料:
カラム IgG Purification Kit-A (コスモバイオ#AP01)
抗体 Normal Rabbit IgG(シグマ・アルドリッチ社製)
磁性化合物 化合物8
磁性抗体 化合物10
(磁性Rabbit IgG抗体(0.8mg/200μL(生理食塩水)の50μLをプロテインAの精製に使用)
(1)化合物10の精製に使用するカラムが詰まると精製できなくなってしまうので、軽く遠心をして、溶解している上清50μLを精製した。
(2)(1)のサンプル50μLとwash buffer 50μLを混合した。
(3)プロテインAカートリッジに(2)を入れた(2min)。
(4)(3)のカートリッジを8000Gで遠心分離した(30秒)。
(5)(4)にwash buffer 200μL
を加えた。
(6)再度、8000Gで遠心分離した(30秒)。
(7)新しいチューブにcatching buffer 60μLを入れ、これに(6)のカートリッジの内容物を移した。
(8)(7)のチューブにElution buffer 70μLを加え、磁性抗体をcatching buffer に溶出させた。
Claims (1)
- 磁性発現のためのエッセンシャルポーションがリンカーを介して抗体に結合された磁性抗体であって、前記エッセンシャルポーションが金属サレン錯体化合物であり、
抗原の一つの又は複数のエピトープに対する結合能を有し、
個体に投与された後でも、体外からの磁場によって目的領域に誘導されて蓄積されながら、前記金属サレン錯体化合物によって、前記目的領域の標的抗原との抗原抗体反応が実現される、
下記式1で示される磁性抗体であって、
〔式1〕
式中、a1、a2、a3、そして、a4は、夫々抗体であり、
前記金属サレン錯体化合物は、前記抗体のFc領域が前記標的抗原のFcレセプターに結合することが阻害されないように、当該抗体に結合した、
前記磁性抗体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015050042A JP6681144B2 (ja) | 2015-03-12 | 2015-03-12 | 磁性抗体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015050042A JP6681144B2 (ja) | 2015-03-12 | 2015-03-12 | 磁性抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016169182A JP2016169182A (ja) | 2016-09-23 |
JP6681144B2 true JP6681144B2 (ja) | 2020-04-15 |
Family
ID=56983220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015050042A Active JP6681144B2 (ja) | 2015-03-12 | 2015-03-12 | 磁性抗体 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6681144B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7184282B2 (ja) * | 2018-12-13 | 2022-12-06 | 株式会社Ihi | 金属アセン錯体を含む薬剤送達システム |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5408905B2 (ja) * | 2008-05-27 | 2014-02-05 | 義弘 石川 | 抗体又は抗原の定量方法 |
RU2533567C2 (ru) * | 2010-04-06 | 2014-11-20 | АйЭйчАй КОРПОРЕЙШН | Производные комплекса металл-сален и способ их получения |
JP2012176905A (ja) * | 2011-02-25 | 2012-09-13 | Ihi Corp | 金属サレン錯体化合物 |
JP2014210742A (ja) * | 2013-04-19 | 2014-11-13 | 株式会社Ihi | 持続性磁性抗がん剤 |
-
2015
- 2015-03-12 JP JP2015050042A patent/JP6681144B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016169182A (ja) | 2016-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022018119A (ja) | プロリンロックドステープルドペプチドおよびその用途 | |
JP2933740B2 (ja) | タンパク質および他のアミン含有化合物を標識するのに有用なジオキシム配位子へのボロン酸付加物の金属錯体 | |
Oberhausen et al. | Synthesis and characterization of dinuclear copper (II) complexes of the dinucleating ligand 2, 6-bis [(bis ((1-methylimidazol-2-yl) methyl) amino) methyl]-4-methylphenol | |
KR100346795B1 (ko) | 헤테로원자-포함 리간드 및 이의 금속 착화합물 | |
JP6964352B2 (ja) | 金属を用いた細胞外小胞の分離方法 | |
JP2020528766A (ja) | 陽イオンを利用した細胞外小胞体の分離方法 | |
WO2014065860A1 (en) | Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions | |
Imberti et al. | Tuning the properties of tris (hydroxypyridinone) ligands: efficient 68 Ga chelators for PET imaging | |
EP2657223A1 (en) | Metal-salen complex compound and production method for same | |
Chiang et al. | Photoinduced NO and HNO production from mononuclear {FeNO} 6 complex bearing a pendant thiol | |
TW202043289A (zh) | 包含配位子、間隔區、胜肽連接子及生物分子之複合體 | |
JP2015155407A (ja) | キレート剤 | |
CN103547290A (zh) | 靶向造影剂及其用途 | |
JP6681144B2 (ja) | 磁性抗体 | |
Fisher et al. | Trivalent Gd-DOTA reagents for modification of proteins | |
US9592219B2 (en) | Self-magnetic metal-salen complex compound | |
Cowley et al. | Bifunctional chelators for copper radiopharmaceuticals: the synthesis of [Cu (ATSM)–amino acid] and [Cu (ATSM)–octreotide] conjugates | |
JP2020520998A (ja) | 鉄(iii)mri造影剤として使用するための化合物 | |
JP2014210742A (ja) | 持続性磁性抗がん剤 | |
WO2013061724A1 (ja) | ラジカル抑制剤 | |
Niklas et al. | Chiral quadridentate ligands derived from amino acids and some zinc complexes thereof | |
US6660246B1 (en) | Ligands and metal complexes thereof | |
WO1992011039A1 (en) | Derivatized tris-catechol chelating agents | |
WO2024109935A1 (zh) | 芦竹碱-铂(iv)配合物及其制备方法和抗肿瘤用途 | |
JP2024520899A (ja) | アルデヒドのin vivo検出のための分子プローブ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190606 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191009 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20191017 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200303 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200323 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6681144 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |